Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $7.3 million.

  • Zenas BioPharma's Share-based Compensation rose 158.04% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 275.51%. This contributed to the annual value of $10.8 million for FY2024, which is 209.61% up from last year.
  • Zenas BioPharma's Share-based Compensation amounted to $7.3 million in Q3 2025, which was up 21.36% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Share-based Compensation ranged from a high of $7.3 million in Q3 2025 and a low of $947,000 during Q1 2024.
  • For the 3-year period, Zenas BioPharma's Share-based Compensation averaged around $3.5 million, with its median value being $2.8 million (2024).
  • Data for Zenas BioPharma's Share-based Compensation shows a peak YoY soared of 468.74% (in 2025) over the last 5 years.
  • Over the past 3 years, Zenas BioPharma's Share-based Compensation (Quarterly) stood at $1.1 million in 2023, then spiked by 384.14% to $5.5 million in 2024, then soared by 158.04% to $7.3 million in 2025.
  • Its Share-based Compensation was $7.3 million in Q3 2025, compared to $6.0 million in Q2 2025 and $5.4 million in Q1 2025.